A detailed history of Handelsbanken Fonder Ab transactions in United Therapeutics Corp stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 13,000 shares of UTHR stock, worth $4.85 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
13,000
Previous 10,800 20.37%
Holding current value
$4.85 Million
Previous $3.44 Million 35.44%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$311.04 - $363.55 $684,288 - $799,810
2,200 Added 20.37%
13,000 $4.66 Million
Q2 2024

Aug 05, 2024

SELL
$228.26 - $319.04 $205,434 - $287,136
-900 Reduced 7.69%
10,800 $3.44 Million
Q1 2024

May 13, 2024

BUY
$210.76 - $249.51 $653,356 - $773,481
3,100 Added 36.05%
11,700 $2.69 Million
Q4 2023

Feb 01, 2024

BUY
$214.88 - $256.94 $150,416 - $179,858
700 Added 8.86%
8,600 $1.89 Million
Q3 2023

Oct 19, 2023

BUY
$211.82 - $248.24 $127,092 - $148,944
600 Added 8.22%
7,900 $1.78 Million
Q1 2023

Apr 28, 2023

BUY
$212.99 - $276.17 $298,186 - $386,638
1,400 Added 23.73%
7,300 $1.64 Million
Q2 2022

Aug 03, 2022

SELL
$174.81 - $241.14 $139,848 - $192,912
-800 Reduced 11.94%
5,900 $1.39 Million
Q4 2021

Feb 08, 2022

SELL
$184.32 - $216.08 $479,232 - $561,808
-2,600 Reduced 27.96%
6,700 $1.45 Million
Q3 2021

Nov 10, 2021

BUY
$179.86 - $214.88 $323,748 - $386,784
1,800 Added 24.0%
9,300 $1.72 Million
Q2 2021

Aug 03, 2021

SELL
$170.47 - $211.93 $136,376 - $169,544
-800 Reduced 9.64%
7,500 $1.35 Million
Q4 2020

Feb 11, 2021

BUY
$101.87 - $151.79 $152,805 - $227,685
1,500 Added 22.06%
8,300 $1.26 Million
Q2 2020

Aug 13, 2020

BUY
$92.74 - $125.82 $630,632 - $855,576
6,800 New
6,800 $823,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.